Sakar Healthcare, a significant player in the pharmaceutical industry, has formed a partnership with Zydus Lifesciences to distribute oncology products across GCC (Gulf Cooperation Council) countries. This move comes as part of Sakar's expanding portfolio, having already secured 40 global alliances in the anti-cancer sector.

Sakar Healthcare has sealed its 40th deal with Zydus Lifesciences for oncology products in the Gulf Cooperation Council (GCC) and emerging markets. The company has submitted 23 Marketing Authorizations (MAs) in the EU, received 5 approvals, and is concentrating on API development and integration within the healthcare sector.

Sakar Healthcare experienced an 8.3% increase in stock price today, reaching Rs 754.4, following a significant purchase by Stellar Wealth Partners. The investment firm acquired approximately 1.95 lakh shares, representing a 0.88% stake at Rs 664.6 per share.

Sakar Healthcare anticipates significant expansion in fiscal year 2027, largely due to increased export sales. The company also expects growing oncology patient numbers to bolster their growth trajectory.

Sakar Healthcare Limited experienced a 20% surge in share price today due to impressive fiscal year 2026 results showing profit doubling and revenue growth of 41%. This growth can be attributed to effective debt reduction, strong cash flows, and increased EPS, indicative of financial discipline and operational efficiency.

Sakar Healthcare reports a significant 67% year-on-year increase in Q4 EBITDA, with the figure reaching ₹262 million. This growth has led to an improvement in the company's earnings margin, which now stands at 36.9%.